![genentech-logo-750 Genentech, a member of the Roche Group, logo](https://www.curesma.org/wp-content/uploads/2019/07/genentech-logo-750.png)
Genentech recently issued an SMA community statement highlighting updates from the 2023 SMA Research & Clinical Care Meeting.
These updates included:
- Investigating risdiplam treatment post gene-therapy
- Long-term efficacy and safety of risdiplam
- Real-world evidence generation
Check out the full community statement here.